Holen Sie sich die Stockscreener-App
1.0839
0.00%
0.0061
Handel nachbörslich:
1.08
-0.0039
-0.36%
Schlusskurs vom Vortag:
$1.09
Offen:
$1.09
24-Stunden-Volumen:
179.54K
Relative Volume:
0.67
Marktkapitalisierung:
$12.59M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-8.70M
KGV:
-0.7207
EPS:
-1.5039
Netto-Cashflow:
$-7.99M
1W Leistung:
+2.83%
1M Leistung:
-8.40%
6M Leistung:
-11.38%
1J Leistung:
-37.71%
1-Tages-Spanne:
$1.08
$1.1108
1-Wochen-Bereich:
$1.06
$1.13
52-Wochen-Spanne:
$0.8127
$4.1899
Phio Pharmaceuticals Corp Stock (PHIO) Company Profile
Firmenname
Phio Pharmaceuticals Corp
Sektor
Branche
Telefon
(508) 767-3861
Adresse
411 SWEDELAND ROAD, KING OF PRUSSIA, MA
Compare PHIO vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PHIO
Phio Pharmaceuticals Corp
|
1.0839 | 12.66M | 0 | -8.70M | -7.99M | -1.5039 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Phio Pharmaceuticals Corp Stock (PHIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-05 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-08-05 | Eingeleitet | H.C. Wainwright | Buy |
Phio Pharmaceuticals Corp Aktie (PHIO) Neueste Nachrichten
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series - TMX Newsfile
Skin cancer treatment PH-762: Phio live Q&A session May 28 - Stock Titan
PHIO Q1 2026 Earnings: EPS Misses Estimates as Research-Focused Biotech Maintains Development Pace - Newser
PHIO Stock Price, Quote & Chart | PHIO PHARMACEUTICALS CORP (NASDAQ:PHIO) - ChartMill
Phio Pharmaceuticals Announces "Innovations in Skin Cancer Treatment and Prevention" in a Fireside Chat with Force Family Office on Tuesday, May 19, 2026 - TMX Newsfile
Phio Pharmaceuticals (PHIO) Q1 2026 Results Miss Estimates — EPS $-0.34 vs $-0.24Product Mix - newser.com
Phio Pharmaceuticals Corp.Common Stock (NQ:PHIO) - FinancialContent
PHIO Should I Buy - Intellectia AI
TradingKey - TradingKey
Skin cancer drug hits 65% response; doctor, CEO to discuss what's next - Stock Titan
MSN Money - MSN
Why Phio Pharmaceuticals (PHIO) could be the turning point you've been waiting for (-0.87%) 2026-05-07Fast Rising Picks - newser.com
Phio Pharmaceuticals Corp. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Phio Pharmaceuticals (NASDAQ: PHIO) boosts PH-762 spending as Q1 2026 loss grows - Stock Titan
Phio Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update - TMX Newsfile
Skin cancer drug trial wraps at Phio, FDA submission targets Q2 - Stock Titan
PHIO Q1'26 Earnings: EPS estimate is (0.23) USD - TradingView
Is Phio Pharmaceuticals (PHIO) stock forming a trend channel | Q4 2025: EPS Tops ViewsStrategic Review - Newser
Cancer drug developer Phio sets April 29 live Q&A on clinical progress - Stock Titan
Phio Pharmaceuticals (PHIO) Stock Resistance Rejection (Modest Decline) 2026-04-20Expert Breakout Alerts - Cổng thông tin điện tử tỉnh Lào Cai
Phio Pharmaceuticals Announces "Nobel Prize Winning Science Takes on Skin Cancer" in a Fireside Chat with Force Family Office on Wednesday, April 15, 2026 - TMX Newsfile
Phio Pharmaceuticals Announces Presentation at Centri Capital Conference on April 14, 2026 - TMX Newsfile
PHIO: RNA immunotherapy shows strong tumor clearance and safety, advancing to next clinical phase - TradingView
Phio Pharmaceuticals to Discuss 'Nobel Prize Winning Science' for Skin Cancer Treatment - National Today
EPS Watch: Is Phio Pharmaceuticals Corp a stock for growth or value investors2026 Trade Ideas & Reliable Volume Spike Trade Alerts - baoquankhu1.vn
User - The Chronicle-Journal
How do market conditions affect Phio Pharmaceuticals (PHIO) Stock | Price at $1.24, Up 2.48%Real Time Stock Idea Network - Newser
Form 8-KCurrent report - ADVFN
Ideas Watch: Does Phio Pharmaceuticals Corp have declining or rising EPSNew Guidance & Risk Controlled Swing Alerts - baoquankhu1.vn
Phio CEO heads to Nasdaq Marketsite for April 14 investor presentation - Stock Titan
Phio Pharmaceuticals Corp. Enters Material Definitive Agreement – SEC 8-K Filing Details April 8, 2026 - Minichart
Phio Pharmaceuticals Establishes New At-the-Market Equity Program - TipRanks
Phio Pharmaceuticals CorpEnters At The Market Offering Agreement With H.C. Wainwright On April 8, 2026 - TradingView
Phio Pharmaceuticals (NASDAQ: PHIO) launches $6.36M at-the-market stock plan - Stock Titan
Phio Pharmaceuticals (PHIO) files $6.36M ATM with H.C. Wainwright - Stock Titan
Pyramid Pharma Services Announces Drug Product Manufacturing Agreement for Phio Pharmaceuticals’ Lead Oncology - EIN News
What dividend growth rate does Phio Pharmaceuticals Corp offer2026 Chart Watch & Real-Time Stock Entry Alerts - baoquankhu1.vn
Will Phio Pharmaceuticals (PHIO) Stock Go Higher | Price at $1.25, Down 2.34%Free Stock Community - Newser
Profit Review: Is Phio Pharmaceuticals Corp on track to beat earningsSwing Trade & Detailed Earnings Play Alerts - baoquankhu1.vn
Phio Pharmaceuticals Announces Agreement with U.S. cGMP Manufacturing Source for Drug Product, PH-762 - TMX Newsfile
VIX Spike: Is Phio Pharmaceuticals Corp being accumulated by smart moneyQuarterly Risk Review & Free Technical Pattern Based Buy Signals - baoquankhu1.vn
Finanzdaten der Phio Pharmaceuticals Corp-Aktie (PHIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Phio Pharmaceuticals Corp-Aktie (PHIO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Bitterman Robert J | Chairman, Pres. & CEO |
Dec 23 '25 |
Buy |
1.02 |
5,000 |
5,100 |
286,421 |
| Bitterman Robert J | Chairman, Pres. & CEO |
Nov 21 '25 |
Buy |
1.14 |
5,000 |
5,700 |
281,421 |
| Bitterman Robert J | Chairman, Pres. & CEO |
Nov 18 '25 |
Buy |
1.27 |
5,000 |
6,350 |
276,421 |
| Bitterman Robert J | Chairman, Pres & CEO |
Jun 10 '25 |
Buy |
2.42 |
2,000 |
4,840 |
27,149 |
| Ferrara Robert L | Director |
Jun 10 '25 |
Buy |
2.42 |
2,500 |
6,050 |
15,666 |
| Bitterman Robert J | Chairman, Pres & CEO |
Jun 09 '25 |
Buy |
2.75 |
1,500 |
4,125 |
25,149 |
1.49%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):